Holen Sie sich die Stockscreener-App
10.38
2.76%
-0.29
Schlusskurs vom Vortag:
$10.67
Offen:
$10.92
24-Stunden-Volumen:
85,138
Relative Volume:
0.18
Marktkapitalisierung:
$526.09M
Einnahmen:
$82.71M
Nettoeinkommen (Verlust:
$-102.24M
KGV:
-2.8283
EPS:
-3.67
Netto-Cashflow:
$-76.57M
1W Leistung:
-9.86%
1M Leistung:
+2.72%
6M Leistung:
-14.40%
1J Leistung:
-20.01%
1-Tages-Spanne:
$10.36
$10.92
1-Wochen-Bereich:
$9.625
$11.64
52-Wochen-Spanne:
$8.94
$20.70
Urogen Pharma Ltd Stock (URGN) Company Profile
Firmenname
Urogen Pharma Ltd
Sektor
Branche
Telefon
972 9 770 7601
Adresse
9 HA'TA'ASIYA ST, RA'ANANA
Vergleichen Sie URGN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
URGN
Urogen Pharma Ltd
|
10.36 | 526.09M | 82.71M | -102.24M | -76.57M | -3.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
432.91 | 128.25B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
542.18 | 63.70B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
558.96 | 39.07B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
255.62 | 33.27B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
232.56 | 27.58B | 3.81B | -644.79M | -669.77M | -6.24 |
Urogen Pharma Ltd Stock (URGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-02-19 | Fortgesetzt | Ladenburg Thalmann | Buy |
| 2024-08-22 | Eingeleitet | Guggenheim | Buy |
| 2023-02-08 | Herabstufung | Jefferies | Buy → Hold |
| 2022-04-27 | Eingeleitet | Berenberg | Buy |
| 2020-04-16 | Bestätigt | H.C. Wainwright | Buy |
| 2020-04-13 | Bestätigt | H.C. Wainwright | Buy |
| 2020-01-09 | Eingeleitet | National Securities | Neutral |
| 2019-05-30 | Eingeleitet | JP Morgan | Neutral |
| 2019-05-29 | Eingeleitet | Goldman | Neutral |
| 2019-01-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-11-08 | Fortgesetzt | Jefferies | Buy |
| 2018-04-04 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2018-01-02 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2017-11-15 | Bestätigt | Oppenheimer | Outperform |
| 2017-11-15 | Herabstufung | Raymond James | Outperform → Mkt Perform |
Alle ansehen
Urogen Pharma Ltd Aktie (URGN) Neueste Nachrichten
FDA to review UroGen’s bladder cancer drug on May 21 By Investing.com - Investing.com Nigeria
UroGen Pharma (URGN) Maintains 'Buy' Rating with $25 Price Target | URGN Stock News - GuruFocus
MetLife Investment Management LLC Has $242,000 Stake in UroGen Pharma Ltd. (NASDAQ:URGN) - Defense World
FDA to host advisory committee meeting on UGN-102 for NMIBC - Urology Times
Stock Market Recap: UroGen Pharma Ltd (URGN) Concludes at 9.69, a -11.51 Surge/Decline - DWinneX
UroGen's bladder cancer treatment to be reviewed by FDA advisory committee - Seeking Alpha
UroGen Announces FDA Advisory Committee for UGN-102, an Investigational Treatment for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer | URGN Stock News - GuruFocus
FDA to review UroGen’s bladder cancer drug on May 21 - Investing.com Australia
UroGen Announces FDA Advisory Committee for UGN-102, an Investigational Treatment for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer - Business Wire
Barclays PLC Buys 9,547 Shares of UroGen Pharma Ltd. (NASDAQ:URGN) - Defense World
UroGen Pharma Ltd. (NASDAQ:URGN) Receives Consensus Rating of “Buy” from Brokerages - Defense World
(URGN) Long Term Investment Analysis - news.stocktradersdaily.com
UroGen Pharma Ltd. (NASDAQ:URGN) Shares Sold by JPMorgan Chase & Co. - Defense World
AUA hoorays in bladder cancer for J&J, Urogen, more - BioWorld MedTech
UroGen Pharma to Report First Quarter 2025 Financial Results on Monday, May 12, 2025 - Business Wire
It makes sense and dollars to buy UroGen Pharma Ltd (URGN) stock - Sete News
Market Highlights: UroGen Pharma Ltd (URGN) Ends on a High Note at 11.64 - DWinneX
Legal & General Group Plc Boosts Stake in UroGen Pharma Ltd. (NASDAQ:URGN) - Defense World
HC Wainwright Predicts UroGen Pharma Q1 Earnings - Defense World
UroGen Pharma’s (URGN) Buy Rating Reaffirmed at Guggenheim - American Banking and Market News
Guggenheim Reaffirms Buy Rating for UroGen Pharma (NASDAQ:URGN) - Defense World
Should investors be concerned about UroGen Pharma Ltd (URGN)? - uspostnews.com
Examining the Potential Price Growth of UroGen Pharma Ltd (URGN) - knoxdaily.com
UroGen Pharma Ltd Inc. (URGN) Price Performance: The Role of Supply and Demand - investchronicle.com
Urogen Pharma (URGN) Moves 14.1% Higher: Will This Strength Last? - Yahoo
Renaissance Technologies LLC Makes New Investment in UroGen Pharma Ltd. (NASDAQ:URGN) - Defense World
UroGen Pharma (NASDAQ:URGN) Receives Buy Rating from D. Boral Capital - Defense World
UroGen Pharma (NASDAQ:URGN) Receives Buy Rating from HC Wainwright - Defense World
Biotech Firm Uncovers Long-Term Cancer Breakthrough in Nevada - streetwisereports.com
UroGen Pharma (URGN) Reports Positive Safety Outcomes in Cancer Study | URGN Stock News - GuruFocus
Let’s Start With The Stock Forecast For UroGen Pharma Ltd (NASDAQ: URGN) - Marketing Sentinel
UroGen Pharma Touts Four-Year Response With Urothelial Cancer Drug Study, Highlights Potential For Bladder Cancer Candidates - Benzinga
UroGen Pharma (URGN) Reports Nearly Four-Year Response Duration for JELMYTO | URGN Stock News - GuruFocus
URGN: UroGen Pharma's UGN-102 Demonstrates Promising Results in Bladder Cancer Treatment | URGN Stock News - GuruFocus
UroGen Pharma Reports Nearly 4-Year Response for Urothelial Cancer Therapy -- Shares Up Pre-Bell - marketscreener.com
New Long-Term Follow-Up Data from OPTIMA II Study of UGN-102 Demonstrates Median Duration of Response of Two Years in Patients with LG-IR-NMIBC - ADVFN
UroGen Pharma (URGN) Updates Promising Results from UGN-102 Tria - GuruFocus
UroGen Pharma (URGN) Reports Promising Long-Term Results for Bla - GuruFocus
OLYMPUS Long-Term Follow-Up Study Reports Nearly Four-Year Durat - GuruFocus
New Patient-Reported Outcomes from UGN-102 Clinical Trials Show - GuruFocus
New Long-Term Follow-Up Data from OPTIMA II Study of UGN-102 Dem - GuruFocus
OLYMPUS Long-Term Follow-Up Study Reports Nearly Four-Year Duration of Response in Subset of Patients with Low-Grade Upper Tract Urothelial Cancer Who Achieved a Complete Response to Initial JELMYTO Treatment - Yahoo
New Patient-Reported Outcomes from UGN-102 Clinical Trials Show the Investigational Treatment Did Not Adversely Affect Functionality, Symptom Burden, and Quality of Life in Patients with LG-IR-NMIBC - ADVFN
UroGen Announces Data Presentations at the American Urological Association 2025 Annual Meeting Highlighting Emerging Evidence Supporting Our Portfolio for Urothelial Cancers - ADVFN
UroGen Announces Updated 18-Month Duration of Response (DOR) of - GuruFocus
UroGen Announces Updated 18-Month Duration of Response (DOR) of 80.6% from the Phase 3 ENVISION Trial of UGN-102, an Investigational Treatment for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC) - Business Wire
UroGen Pharma Announces Encouraging Results from a Phase 1 Dose- - GuruFocus
UroGen Pharma Announces Encouraging Results from a Phase 1 Dose-Escalation Study Evaluating UGN-301 in Non-Muscle Invasive Bladder Cancer - Business Wire
UroGen Pharma Announces Encouraging Results from a Phase 1 Dose-Escalation Study Evaluating UGN-301 in Non-Muscle Invasive Bladder Cancer | URGN Stock News - GuruFocus
How should investors view UroGen Pharma Ltd (URGN)? - uspostnews.com
Wells Fargo & Company MN Boosts Stock Position in UroGen Pharma Ltd. (NASDAQ:URGN) - Defense World
Finanzdaten der Urogen Pharma Ltd-Aktie (URGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
Urogen Pharma Ltd-Aktie (URGN) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Smith Jason Drew | General Counsel |
Jan 31 '25 |
Sale |
11.14 |
7,379 |
82,202 |
26,468 |
| Schoenberg Mark | Chief Medical Officer |
Sep 09 '24 |
Sale |
13.08 |
859 |
11,236 |
145,091 |
| Smith Jason Drew | General Counsel |
Sep 09 '24 |
Sale |
13.08 |
1,521 |
19,895 |
25,226 |
2.11%
0.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):